MFC Co

MFC Co P/B

The P/B (Price-to-Book Ratio) of MFC Co (432980.KQ) as of Nov 6, 2026 is 1.00. In the previous year, P/B (Price-to-Book Ratio) was 1.59 — a change of -37.38% (lower).

P/B

1.00

YoY

-37.38%

Last updated:

P/B (Price-to-Book Ratio) of MFC Co is 2024 1.00 . P/B (Price-to-Book Ratio) of MFC Co was 2023 1.59 . It decreases by -37.38% lower compared to the previous year.

The MFC Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2022
-14.44 KRW
Jan 1, 2023
1.59 KRW
Jan 1, 2024
1.00 KRW
The MFC Co P/B history
YEARP/BYoY
1.00-37.38%
1.59-111.04%
-14.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MFC Co Stock analysis

What does MFC Co do? MFC Co Ltd generates revenue primarily through the development and production of active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials for the pharmaceutical industry. The company focuses on creating basic pharmaceutical substances and raw material pharmaceuticals, serving clients in the pharmaceutical sector. Its products are sold to pharmaceutical manufacturers who require these materials for drug formulation. The company operates within the pharmaceutical research and development segment, targeting firms involved in drug production and formulation. MFC Co Ltd's business model centers on providing essential raw materials and intermediates to pharmaceutical companies. By specializing in API, KSM, and intermediate materials, the company supports the manufacturing processes of its clients. The firm's revenue streams are derived from the sale of these specialized pharmaceutical components to manufacturers who integrate them into their final drug products. The company's target market consists of pharmaceutical manufacturers requiring high-quality raw materials for their production lines. The company's core offerings include active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials, which are critical for pharmaceutical manufacturing. These products are sold to pharmaceutical manufacturers as part of their supply chain. MFC Co Ltd's revenue is generated through the direct sale of these materials to clients in the pharmaceutical industry. The company's focus on R&D for pharmaceutical substances ensures a steady demand for its products from drug manufacturers seeking reliable suppliers. MFC Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MFC Co stock

P/B (Price-to-Book Ratio) of MFC Co is 1.00 in 2024.

P/B (Price-to-Book Ratio) of MFC Co changed from 1.59 to 1.00, representing a -37.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) MFC Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s MFC Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — MFC Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — MFC Co